Higher orexin-A levels are associated with treatment response to clozapine in patients with schizophrenia: A cross-sectional study
Background: Clozapine is the primary antipsychotic (APD) for treatment-resistant schizophrenia (TRS). However, only 40% of patients with TRS respond to clozapine, constituting a subgroup of clozapine-resistant patients. Recently, the neuropeptide orexin-A was shown to be involved […]
